Phenotypes in asthma: Useful guides for therapy, distinct biological processes, or both?

American Journal of Respiratory and Critical Care Medicine

Volumn 170, Issue 6, 2004, Pages 579-580

  Wenzel, Sally E ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; PEPTIDOLEUKOTRIENE; TRIAMCINOLONE;

ASTHMA; BASEMENT MEMBRANE; CLINICAL PROTOCOL; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; EDITORIAL; ENVIRONMENTAL FACTOR; EOSINOPHIL; GENETIC HETEROGENEITY; HUMAN; LOEFFLER PNEUMONIA; LUNG ALVEOLUS EPITHELIUM; NEUTROPHIL; PHENOTYPE; PREDICTION; PRIORITY JOURNAL;

ADRENAL CORTEX HORMONES; ANTI-ASTHMATIC AGENTS; ASTHMA; ENVIRONMENT; EOSINOPHILIA; HUMANS; PHENOTYPE; SEVERITY OF ILLNESS INDEX;

EID: 4444374418     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.2407005     Document Type: Editorial

References (11)

1. Webster's Ninth New Collegiate Dictionary. Springfield MA: Merriam-Webster Inc., 1984.
2. Global Initiative for Asthma: Global Strategy for Asthma Management and Prevention (GINA). National Institutes of Health, National Heart, Lung, and Blood Institute, Bethesda. 2002. p. 1-9.
3. National Asthma Education and Prevention Program Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma Publication No. 97-4051 (NAEPP). US Department of Health & Human Services. 1997.
4. Ayres JG, Miles JF, Barnes PJ. Brittle asthma. Thorax 1998;53:315-321.
5. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J 2003;22:470-477.
6. Wenzel SE, Schwartz LB, Langmack EL, Halliday JL, Trudeau JB, Gibbs RL, Chu HW. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999;160:1001-1008.
7. Miranda C, Busacker A, Balzar S, Trudeau J, Wenzel SE. Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol 2004;113:101-108.
8. Douwes J, Gibson P, Pekkanen J, Pearce N. Non-eosinophilic asthma: importance and possible mechanisms. Thorax 2002;57:643-648.
9. Green RH, Brightling CE, Woltmann G, Parker D, Wardlaw AJ, Pavord ID. Analysis of induced sputum in adults with asthma: identification of a subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002;57:875-879.
10. Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, Wardlaw AJ, Pavord ID. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002;360:1715-1721.
11. ten Brinke A, Zwinderman AH, Sterk PJ, Rabe KF, Bel EH. "Refractory" eosinophilic airway inflammation in severe asthma: effect of parenteral corticosteroids. Am J Respir Crit Care Med 2004;170:601-605.